CA1260471C - - Google Patents

Info

Publication number
CA1260471C
CA1260471C CA 471594 CA471594A CA1260471C CA 1260471 C CA1260471 C CA 1260471C CA 471594 CA471594 CA 471594 CA 471594 A CA471594 A CA 471594A CA 1260471 C CA1260471 C CA 1260471C
Authority
CA
Canada
Prior art keywords
compounds
formula
hydrogon
bronchodilating
inotropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA 471594
Other languages
English (en)
Other versions
CA1251209A (en
Inventor
Robert A Slater
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Priority to CA000581012A priority Critical patent/CA1260471A/en
Application granted granted Critical
Publication of CA1251209A publication Critical patent/CA1251209A/en
Publication of CA1260471C publication Critical patent/CA1260471C/xx
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
CA000471594A 1984-01-13 1985-01-07 DISHYDROPYRIDAZINONE DERIVATIVES Expired CA1251209A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000581012A CA1260471A (en) 1984-01-13 1988-10-21 Dihydropyridazinone derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA000581012A Division CA1260471A (en) 1984-01-13 1988-10-21 Dihydropyridazinone derivatives

Publications (2)

Publication Number Publication Date
CA1251209A CA1251209A (en) 1989-03-14
CA1260471C true CA1260471C (US06291489-20010918-C00077.png) 1989-09-26

Family

ID=10554924

Family Applications (2)

Application Number Title Priority Date Filing Date
CA000471594A Expired CA1251209A (en) 1984-01-13 1985-01-07 DISHYDROPYRIDAZINONE DERIVATIVES
CA000581012A Expired CA1260471A (en) 1984-01-13 1988-10-21 Dihydropyridazinone derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA000581012A Expired CA1260471A (en) 1984-01-13 1988-10-21 Dihydropyridazinone derivatives

Country Status (31)

Country Link
US (1) US4654342A (US06291489-20010918-C00077.png)
EP (1) EP0150937B1 (US06291489-20010918-C00077.png)
JP (3) JPS60158181A (US06291489-20010918-C00077.png)
KR (1) KR920006781B1 (US06291489-20010918-C00077.png)
CN (1) CN85101722A (US06291489-20010918-C00077.png)
AT (1) ATE37179T1 (US06291489-20010918-C00077.png)
AU (1) AU572252B2 (US06291489-20010918-C00077.png)
CA (2) CA1251209A (US06291489-20010918-C00077.png)
CS (1) CS248731B2 (US06291489-20010918-C00077.png)
DD (1) DD231350A5 (US06291489-20010918-C00077.png)
DE (1) DE3564941D1 (US06291489-20010918-C00077.png)
DK (1) DK162519C (US06291489-20010918-C00077.png)
ES (3) ES8607949A1 (US06291489-20010918-C00077.png)
FI (1) FI850140L (US06291489-20010918-C00077.png)
GB (1) GB8400863D0 (US06291489-20010918-C00077.png)
GR (1) GR850068B (US06291489-20010918-C00077.png)
HU (1) HU193591B (US06291489-20010918-C00077.png)
IE (1) IE57969B1 (US06291489-20010918-C00077.png)
IL (1) IL74031A (US06291489-20010918-C00077.png)
JO (1) JO1351B1 (US06291489-20010918-C00077.png)
MY (1) MY100124A (US06291489-20010918-C00077.png)
NO (1) NO850129L (US06291489-20010918-C00077.png)
NZ (1) NZ210816A (US06291489-20010918-C00077.png)
PH (1) PH22136A (US06291489-20010918-C00077.png)
PL (1) PL147123B1 (US06291489-20010918-C00077.png)
PT (1) PT79819B (US06291489-20010918-C00077.png)
RO (1) RO92607A (US06291489-20010918-C00077.png)
SU (1) SU1396963A3 (US06291489-20010918-C00077.png)
WO (1) WO1985003076A1 (US06291489-20010918-C00077.png)
ZA (1) ZA85251B (US06291489-20010918-C00077.png)
ZW (1) ZW385A1 (US06291489-20010918-C00077.png)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
AU2002254124A1 (en) * 2001-02-27 2002-09-12 Mitokor Aryl-n-cyanoguanidines and methods related thereto
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
EP1951227B1 (en) * 2005-11-14 2017-04-12 Boehringer Ingelheim Vetmedica GmbH Use of pimobendan for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
BRPI0921868A2 (pt) 2008-11-25 2015-12-29 Boehringer Ingelheim Vetmed inibidores de fosfodiesterase tipo iii (pde iii) ou agentes de sensibilizacao de ca2+ para o tratamento de cardiomiopatia hipertrofica
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
BR122019024673B1 (pt) 2013-12-04 2023-04-11 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
EP0059688B1 (de) * 1981-03-04 1985-05-15 Ciba-Geigy Ag Pyridazinone, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen und deren Verwendung
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones

Also Published As

Publication number Publication date
EP0150937A2 (en) 1985-08-07
PT79819B (en) 1987-01-07
ZW385A1 (en) 1985-08-07
FI850140A0 (fi) 1985-01-11
ES549629A0 (es) 1987-03-01
EP0150937A3 (en) 1985-08-21
PL251516A1 (en) 1985-12-17
NZ210816A (en) 1987-06-30
KR850005417A (ko) 1985-08-26
IL74031A0 (en) 1985-04-30
GB8400863D0 (en) 1984-02-15
DK9185A (da) 1985-07-14
EP0150937B1 (en) 1988-09-14
HUT37128A (en) 1985-11-28
PH22136A (en) 1988-06-01
ES8703846A1 (es) 1987-03-01
PL147123B1 (en) 1989-04-29
IL74031A (en) 1988-07-31
MY100124A (en) 1989-12-18
JO1351B1 (en) 1986-11-30
ES8607949A1 (es) 1986-06-01
WO1985003076A1 (en) 1985-07-18
NO850129L (no) 1985-07-15
ATE37179T1 (de) 1988-09-15
CS248731B2 (en) 1987-02-12
ZA85251B (en) 1986-08-27
DK162519C (da) 1992-03-30
IE850069L (en) 1985-07-13
KR920006781B1 (ko) 1992-08-17
RO92607A (ro) 1987-11-30
DE3564941D1 (en) 1988-10-20
DK162519B (da) 1991-11-11
PT79819A (en) 1985-02-01
CA1251209A (en) 1989-03-14
FI850140L (fi) 1985-07-14
AU3761185A (en) 1985-07-18
DD231350A5 (de) 1985-12-24
JPS63313775A (ja) 1988-12-21
CN85101722A (zh) 1987-01-31
SU1396963A3 (ru) 1988-05-15
ES8706645A1 (es) 1987-07-01
JPS63313776A (ja) 1988-12-21
ES539446A0 (es) 1986-06-01
US4654342A (en) 1987-03-31
AU572252B2 (en) 1988-05-05
IE57969B1 (en) 1993-06-02
JPS60158181A (ja) 1985-08-19
GR850068B (US06291489-20010918-C00077.png) 1985-05-03
HU193591B (en) 1987-11-30
ES554965A0 (es) 1987-07-01
DK9185D0 (da) 1985-01-08
CA1260471A (en) 1989-09-26

Similar Documents

Publication Publication Date Title
CA1260471C (US06291489-20010918-C00077.png)
AU1507888A (en) New bicyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same
PT84760A (en) Heterocyclic compounds
DE3465594D1 (en) Tropone derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
ES8302719A1 (es) Un procedimiento para preparar compuestos de cefem
NZ216741A (en) 6-oxo-1,6-dihydropyridazines and pharmaceutical compositions

Legal Events

Date Code Title Description
MKEX Expiry